{"id":4258,"date":"2026-11-11T09:00:00","date_gmt":"2026-11-11T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=4258"},"modified":"2026-11-12T20:57:25","modified_gmt":"2026-11-13T00:57:25","slug":"amgen-details-phase-3-dazodalibep-results-in-sjogren-disease","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=4258","title":{"rendered":"Amgen Details Phase 3 Dazodalibep Results in Sjogren Disease"},"content":{"rendered":"<p><img fetchpriority=\"high\" decoding=\"async\" width=\"768\" height=\"512\" src=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261112_Amgen_Dazodalibep_Therapeutic_Indications-768x512.png\" alt=\"\" class=\"attachment-medium_large size-medium_large wp-image-4283\" srcset=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261112_Amgen_Dazodalibep_Therapeutic_Indications-768x512.png 768w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261112_Amgen_Dazodalibep_Therapeutic_Indications-300x200.png 300w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261112_Amgen_Dazodalibep_Therapeutic_Indications-1024x683.png 1024w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261112_Amgen_Dazodalibep_Therapeutic_Indications.png 1536w\" sizes=\"(max-width: 768px) 100vw, 768px\" \/><\/p>\n<p><strong>Company<\/strong><\/p>\n<p>Amgen<\/p>\n<p><strong>Event Type<\/strong><\/p>\n<p>Detailed Phase 3 results (OASIZ-301)<\/p>\n<p><strong>Modality<\/strong><\/p>\n<p>Fusion protein<\/p>\n<p><strong>Asset<\/strong><\/p>\n<p>Dazodalibep<\/p>\n<p><strong>Target<\/strong><\/p>\n<p>CD40L<\/p>\n<p><strong>Disease Area<\/strong><\/p>\n<p>Sj\u00f6gren disease<\/p>\n<h4>Summary<\/h4>\n<p>Recovered 36-hour item: Amgen disclosed detailed randomized Phase 3 OASIZ-301 results November 11 after earlier topline news. Both dazodalibep dose schedules improved systemic disease activity at week 48 versus placebo in Sj\u00f6gren disease.<\/p>\n<p>In 648 randomized patients, the 1,500-mg every-four-week arm reduced ESSDAI 5.6 points versus 3.8 for placebo, placebo-adjusted 1.8 points (adjusted P&lt;0.001). The 3,000-mg every-12-week arm reduced 5.2 versus 3.8, difference 1.4 (P=0.010). The monthly arm also improved reported dryness. Serious adverse events and adverse-event discontinuations were described as balanced; granular tables await presentation.<\/p>\n<h4>Deep Analysis<\/h4>\n<p><strong>Interpretation A:<\/strong> CD40L inhibition may offer systemic and symptom benefit in a disease without an approved US therapy. Support: prespecified randomized endpoint, two active regimens and a patient-reported symptom signal. Against: the absolute ESSDAI difference is modest, and symptom benefit was highlighted for one schedule.<\/p>\n<p><strong>Interpretation B:<\/strong> clinical uptake may hinge on subgroup and durability rather than statistical significance. Support: heterogeneous manifestations and infusion schedules. Against: early onset and week-48 persistence support plausibility. Full effect distributions, steroid exposure, fatigue and organ subgroups, long-term thromboembolic and infection safety, and OASIZ-303 results would upgrade or weaken the case. No regulatory approval should be inferred.<\/p>\n<h4>Company and Product Background<\/h4>\n<p>Dazodalibep is a CD40L antagonist fusion protein intended to interrupt T-cell, B-cell and antigen-presenting-cell signaling. Sj\u00f6gren disease causes glandular dryness and systemic immune injury.<\/p>\n<h4>Signal Extraction<\/h4>\n<ul>\n<li>Verified: dated company release and randomized study design.<\/li>\n<li>Independent peer review of complete Phase 3 data remains pending.<\/li>\n<li>Missing: full protocol-linked subgroup and safety tables.<\/li>\n<li>The ACR meeting is a future venue for further detail, not a separate outcome.<\/li>\n<\/ul>\n<h4>InSilens Take<\/h4>\n<p>The randomized systemic endpoint is a consequential step for CD40L inhibition in Sj\u00f6gren disease. The modest absolute difference and schedule-specific symptom signal make full safety, organ-level benefit and durability data decisive for clinical value.<\/p>\n<h4>Signal Assessment<\/h4>\n<p>Signal Importance: 5 of 5. Signal Direction: positive. Confidence in Facts: high. Confidence in Interpretation: moderate.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Recovered 36-hour item: Amgen disclosed detailed randomized Phase 3 OASIZ-301 results November 11 after earlier topline news. Both dazodalibep dose schedules improved systemic disease activity at week 48 versus placebo in Sj\u00f6gren disease.<\/p>\n","protected":false},"author":1,"featured_media":4283,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[180,836,1454],"class_list":["post-4258","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-therapeutic-indication","tag-amgen","tag-dazodalibep","tag-sjogren-disease-2"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4258","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4258"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4258\/revisions"}],"predecessor-version":[{"id":4285,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4258\/revisions\/4285"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/4283"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4258"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4258"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4258"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}